This paper describes a rapid method to determine aceglutamide (ACE) and oxiracetam (OXI) present in an injection formulation using reversed-phase high-performance liquid chromatography. The method was validated with respect to suitability, linearity, accuracy, precision and robustness. Chromatography was carried out on an Elite SinoChrom ODS-BP C18 (5 mm, 250 3 4.60 mm) column with an isocratic mobile phase composed of methanol-phosphate buffer (pH 3.0) in the ratio of 5:95, v/v, at a flow rate of 1.0 mL/min. Detection was carried out using a UV-PDA detector at 210 nm. The linearity range for ACE and OXI were 10-500 and 10-300 mg/mL, respectively. The relative standard deviations for replicate measurements were always <2%.
Introduction
Senile dementia represents an important health problem as the aging people are growing in mainland China today. However, there is still lack of effective drugs for the management of this symptom (1) . Aceglutamide (ACE) is the acetyl derivative of the amino acid L-glutamine ( Figure 1 ). This drug is a psychostimulant and nootropic, which has been attempted to improve memory and concentration. Oxiracetam (OXI) (4-hydroxy-2-oxo-l-pyrrolidineacetamide) is a nootropic drug of the racetam family ( Figure 1 ) and has been used to treat some organic brain syndromes and senile dementia (2 -8) .
Liquid chromatographic (LC) methods have been reported for the analysis of OXI in biosamples (9) (10) (11) (12) and related substances in ACE injections (13) . Because these two drugs can be used together for dealing with cognitive disorder, there is a need for the simultaneous determination of ACE and OXI. However, no HPLC method related to the simultaneous estimation of the two drugs has ever been reported in the literature. In this paper, the established method was validated with respect to specificity, precision, limit of detection (LOD) and limit of quantitation (LOQ), linearity, accuracy and robustness in order to ensure the compliance in accordance with ICH guidelines. The resulting analytical method was applied to monitor the content of the two active compounds in injection formulation samples.
Experimental
Instrumentation A Dionex HPLC system equipped with a 20-mL loop, a P680 pump, a TCC-100 thermostatted column compartment and a PDA-100 photodiode array (PDA) detector was utilized. The chromatographic system was integrated via Chromeleon software system.
Reagents and chemicals
Acetonitrile and methanol were of HPLC grade and supplied by Honeywell. Phosphoric acid and monopotassium phosphate were obtained from TEDIA. HPLC-grade water was prepared using Aike water purification system (Chengdu, China). The ACE and OXI reference standards were purchased from Chinese National Institutes for Food and Drug Control. The injection dose consisting of ACE and OXI was kindly supplied by a local pharmacy.
Chromatographic condition
The isocratic mobile phase consisted of methanol -phosphate buffer ( pH 3.0) in the ratio of 5:95, v/v, flowing through the column at a constant flow rate of 1.0 mL/min. An Elite SinoChrom ODS-BP C18 (5 mm, 250 Â 4.6 mm) column was used as the stationary phase, and 210 nm was selected as the detection wavelength for PDA detector.
Standard preparation
Standard stock solution Standard stock solutions of ACE and OXI of 1,000 mg/mL were prepared separately in a 100 mL volumetric flask by dissolving 100 mg of each drug in methanol.
Working standard solution
The preset concentrations of mixed ACE and OXI ranging from 10 to 500 and 10 to 300 mg/mL were prepared from standard stock solutions with mobile phase.
Sample preparations
The compound injection formulation containing 0.25 g ACE and 1.00 g OXI per dosage was first diluted in a 100-mL flask to volume with methanol to get 2,500 mg/mL ACE and 10,000 mg/mL OXI, and further dilution was carried out by transferring 1 mL of just prepared solutions to another 50 mL flask, diluted to volume with the mobile phase and mixed to contain the equivalent of 50 mg of ACE and 200 mg of OXI per mL.
Results and discussion

Chromatography
Analytical C18 columns with different packing materials were first tested, including SinoChrom ODS-BP C18 column (5 mm, 250 Â 4.6 mm), Kromasil BDS C18 column (5 mm, 250 Â 4.6 mm) and Hypersil BDS C18 column (5 mm, 250 Â 4.6 mm).
Comparing with other types, the SinoChrom ODS-BP C18 column which had strong retention performance in aqueous mobile phase was fit for the separation of hydrophilic samples.
The mobile phase composition was investigated to optimize the separation of the two drugs by several trials. Initially, acetonitrile was selected as the organic modifier. The ratio of acetonitrile varied, but the two components could not be separated throughout. Methanol was then chosen instead of acetonitrile, and the separation status was obviously improved. However, the resolution was poor when the volume ratio of methanol was high. It was ameliorated as methanol took lower percentage than 10%. Phosphate buffers with different pH values ( pH 4.0, 3.5 and 3.0) were also tested. The resolution was better while pH decreased. Eventually, the isocratic mobile phase consisted of methanol -phosphate buffer ( pH 3.0) in the ratio of 5:95 v/v was picked out as the optimal one. In this condition, the resolution of the two drugs was 1.67 (.1.50), indicated that the two components were separated completely.
Although l max for both ACE and OXI are ,200 nm, 210 nm was selected as the detection wavelength for PDA detector considering methanol's cut-off wavelength is 205 nm.
Good separation was achieved and the retention times of ACE and OXI were determined as 4.78 and 3.95 min, respectively ( Figure 2 ).
Method validation
The developed method was validated according to the ICH guidelines (14) under such parameters as system suitability, linearity, LOD, LOQ, accuracy, precision and robustness.
System suitability test
The system suitability parameters summarized in Table I were within acceptable boundary. The number of theoretical plates for ACE and OXI were more than 4,000 and 5,000, respectively. The symmetry of the peaks were ,1.5.
Linearity
ACE and OXI showed a linearity of response between 10 -500 and 10 -300 mg/mL, respectively. The linear relationship between the peak area and the analyte concentration was confirmed through the "lack of fit" test. The F-test on lack of fit at 95% confidence level was performed and it exhibited nonsignificance. The linear regression equation is represented in Table II , where y is the peak area at 210 nm in mAU . min and x is the analyte concentration in mg/mL.
LOD and limit of quantitation (LOQ) were calculated using the following equation:
where s is the standard deviation of the response and S is the slope of the calibration curve.
Accuracy
Three different concentration levels (80, 100 and 120%) of standard drugs were added to a pre-analyzed sample solution for accuracy tests. The results are summarized in Table III . The average recovery ranged from 98.47 to 101.63% confirmed the accuracy of the method. Precision Repeatability As shown in Table IV , three dilutions in six replicates were analyzed in the same day for the repeatability test, and the results were found within acceptable limits [relative standard deviation (RSD) ,2%].
Intermediate precision
As shown in Table V , three dilutions in six replicates were analyzed on two different days and by two analysts for day-to-day and analyst-to-analyst variation. It was found that the RSD value for ACE was higher than that of OXI, this was largely due to its low concentration; however, all results fell in the acceptable limits (RSD ,2%).
Robustness
As summarized in Table VI , small but deliberate variations were made to check the method's robustness. The composition and pH of the mobile phase had a considerable effect on the retention of the two analytes, whereas the flow rate and column temperature had little influence on chromatographic behavior.
Stability of sample solution
As shown in Table VII , the diluted sample solution injected after 12 h was stable. No appreciable changes were observed during the procedure.
Injection solutions analysis
Contents of ACE and OXI found in the injection solutions by the proposed method are shown in Table VIII . The low RSD values indicate that the method is precise and accurate.
Conclusion
An RP-HPLC method was developed and validated for simultaneous estimation of ACE and OXI in the injection dosage form. The proposed method is fast, accurate, precise, and sensitive. Hence, it can be employed for routine quality control of injections containing the two drugs in industries.
